SOURCE: Nutter McClennen & Fish
BOSTON, MA--(Marketwire - Nov 15, 2012) - Speaking before nearly 200 invited guests at Acceleration 2012, the Nutter Early Stage Life Science Conference, keynote speaker Robert Langer of the Massachusetts Institute of Technology and distinguished panels of biotech, pharmaceutical and medical device executives and investors emphasized three key factors -- alignment, strategic planning and flexibility -- as critical to life science companies attracting investment and reaching an attractive exit opportunity.
"Nutter's Acceleration conference brings together executives and investors to discuss solutions to the daunting challenges confronting biotech, pharmaceutical and medical device companies as they seek to commercialize scientific discoveries and build successful companies," said Michelle Basil, partner and chair of the Life Sciences Group of Nutter McClennen & Fish LLP.
"This evening's discussion," said Basil, "highlighted the importance of alignment between companies and investors, strategic planning for achieving clinical and financing milestones, and flexibility for coping with inevitable technology, regulatory and reimbursement challenges."
In addition to Langer, the second annual conference featured one panel focused on innovative early-stage funding models and deal structures in the life sciences and a second panel concentrating on developing strategic business development plans for managing regulatory and reimbursement risks, attracting angel and VC funding, establishing effective strategic partnerships and reaching a successful exit. The event was co-sponsored by Halloran Consulting Group and Silicon Valley Bank.
Omar Amirana, Allied Minds
Alexis Borisy, Third Rock Ventures
David Donabedian, Locust Walk Partners
Paul LaViolette, SV Life Sciences
Bill McPhee, Praxis Advisors
Leslie Williams, ImmusanT
Susan Windham-Bannister, Massachusetts Life Sciences Center
The Life Sciences Group of Nutter McClennen & Fish LLP represents companies involved in innovative technologies in the medical device, biotechnology and pharmaceutical industries, as well as renowned medical institutions and research universities, emerging growth companies and angel and venture capital firms. The firm provides services in capital raising and corporate finance; IP strategy, prosecution and litigation; strategic collaborations and licensing; M&A, trade secret and non-compete litigation; and product liability defense. Nutter is a full service Boston law firm recognized by Johnson & Johnson as a "Go-To Law Firm" in Intellectual Property and Torts Litigation, with top-tier ratings in all of the leading national surveys and rankings of law firms. Information is available at www.nutter.com.